Archival Material Clause Samples

Archival Material. 15.1 All material of archival value produced by or for the OCOG will be collected and organized by the OCOG, and preserved and maintained by Vancouver in accordance with the provisions of the Bid City Agreement and the Host City Contract. 15.2 Subject to section 15.1, the Parties will be entitled to use free of charge, before, during and after the Games Period, copies of any material prepared for or by the OCOG for purposes of developing and distributing sport promotional literature, films, photographs and video material for presentations in any other appropriate medium and for the preparation of such education materials as the COC, Vancouver or Whistler may from time to time determine but not for the purposes of marketing, licensing or any other form of fund raising. The OCOG will provide, without cost, such consents in writing as may be necessary or desirable for such purposes.
View SourceView Similar (2)
Archival Material. Payments due under this Paragraph B from the exploitation of archival material -- “archival” is defined for the purposes of this Agreement as material captured prior to August 1, 2006 -- shall be made to those who were Met employees represented by AGMA at the time the material was captured (including extra AGMA employees who performed in the captured material). In the case of any such AGMA employee who is deceased, the payment due to that employee will be made to the employee’s beneficiary. If an AGMA member (or a beneficiary of a deceased member) cannot be located by the Met or AGMA after a reasonable period of time, then the amount due will be divided equally among the retired Met AGMA members (and beneficiaries, if located, of those deceased) at the time payment is made.
View Source
Archival Material. From and after the Closing Date, the archives of ----------------- the US Toxicology Business shall be transferred to the Buyer and retained by the Buyer (to the extent required by Good Laboratory Practice) at the facilities of the US Toxicology Business in New Jersey.
View Source
Archival Material. “Hails Integrated System at Simpson Rd. Supermarket”, The Atlanta Inquirer. (Atlanta: 1964). The Ida Pearle and Joseph Cuba Community Archives of the William Breman Jewish Heritage Museum. “Hersch’s Super Value Market”, Harold Hersch Family Paper, 1934-1991. Box MSS 193, container 1. Hirsch, Benjamin. Home Is Where You Find It. iUniverse, Inc., 2006. Lasoski, Rebecca. Helen Przerchadski Lasoski: Journey From Nazi Persecution to the Big Easy. American Digital Services, 2011. Baron, Albert, #10055. Interview by John Kent. The Legacy Project in The Ida Pearle and Joseph Cuba Archives of The William Breman Jewish Heritage and Holocaust Museum, 17 January 2001. Bunzl, Francis Hamburger, #10366. Interview by Sarah Ghitis. The Legacy Project in The Ida Pearle and Joseph Cuba Archives of The William Breman Jewish Heritage and Holocaust Museum, 13 December 2005. , #10103. Interview by Ray Ann Kremer. The Legacy Project in The Ida Pearle and Joseph Cuba Archives of The William Breman Jewish Heritage and Holocaust Museum, 9 December 1985. Dziewinski, Maria, #10166. Interview by John Kent. The Legacy Project in The Ida Pearle and Joseph Cuba Archives of The William Breman Jewish Heritage and Holocaust Museum, 4 June 2001.
View Source
Archival Material. Archivo General de Indias (AGI), Audiencia de Santo Domingo -49 -868, L1, f3v. Archivo General de Indias (AGI), Indiferente General -Leg. 418, I F. 150v. -Leg. 418. tomo III, f. 249. -419, L4, f83 -419, L5, ff68-71 -419, L7, f156v. -420, L8 ff93r-93v. -420, L10, ff243r-243v; -421, 42, ff216r-216v. -1624 Archivo General de Indias (AGI), Justicia -6, N4 Archivo General de Indias (AGI), Patronato Real -172, R35 -174 -II, 170, Ramo 14 . Archivo General de Simancas, Consejo Real, Procesos -Leg. 97, fol. 7 Archivo Nacional de Cuba, -Documento Secreto 243, Legajo 3, No. 97a, ff24-33 Coleccion de documentos inéditos relativos al descubrimiento, conquista y organización de las antiguas posesiones españolas de América y Oceanía. 42 volúmenes, Madrid, 1864-1884. [Inéditos América y Oceanía] -XXXI, 3 sig. -XXXI, 18-19, 20, 31, 41, 57 -XXXI, 21 -XXXI, 48 -XXXI, 54 -XXXI, 111 -XXXI, 165-174 -XXXI, 172 -XXXI, 174-179 -XXXI, 214 sig. -XXXI, 519-521 -XXXII, 60-65 -XXXVI, 257-263 Colección de documentos inéditos relativos al descubrimiento, conquista y organización de las antiguas posesiones españolas de ultramar. 18 volumenes, Madrid, 1885. [Documentos Inéditos Ultramar]. -IX, 53-70 Informes, Instrucciones, Memoriales y Relaciones -Despacho del Gobernador Ovando: 1501-1502. -Información sobre La Española. Sevilla, 17 de junio de 1546.
View Source
Archival Material. 16.1 Complete sets of all memorabilia including but not limited to pictures, audio-visuals, banners and medals will be retained by the Host Society until the completion of the Games, and one complete set will be provided at no cost, to the Council, Canada, Nova Scotia, and the Halifax Regional Municipality for archival purposes. 16.2 The Council and the Host Society will work closely with the Halifax Regional Municipality to clarify the requirements for the Halifax Regional Municipality and the Council to
View Source

Related to Archival Material

  • Confidential Material (a) Each Bank agrees that any information, documentation or materials provided by each Borrower or such Borrower’s Affiliates, trustees, directors, officers, employees, agents or representatives (“Representatives”) disclosing the portfolio holdings of such Borrower or disclosing other non-public information in relation to this Agreement or the other Loan Documents (“Confidential Material”), whether before or after the date of this Agreement, shall be treated confidentially, using the same degree of care that such Bank uses to protect its own similar material. (b) Confidential Material may be disclosed to Representatives of each Bank in connection with the transactions contemplated herein or in connection with managing the relationship of such Bank or its Affiliates with such Borrower but shall not be disclosed to any third party and may not be used for purposes of buying or selling securities, including shares issued by such Borrower; provided, however, that the Banks may disclose Confidential Material to (i) the Federal Reserve Board pursuant to applicable rules and regulations promulgated by the Federal Reserve Board (which, as of the Effective Date, require a filing of a list of all Margin Stock which directly or indirectly secures a Loan), (ii) the extent required by statute, rule, regulation or judicial process, (iii) counsel for any of the Banks or the Agent in connection with this Agreement or any of the other Loan Documents, (iv) bank examiners, regulators, auditors and accountants, or (v) any Assignee or Participant (or prospective Assignee or Participant) as long as such Assignee or Participant (or prospective Assignee or Participant) first agrees to be bound by the provisions of this Section 9.09. Notwithstanding anything to the contrary contained in this Section, any information that would, but for this sentence, constitute Confidential Material shall cease to be Confidential Material after the second anniversary of the date such information was first received by the Agent or any Bank.

  • Original Material The description of the material being transferred will be specified in an implementing letter.

  • Promotional Material In the event that the Fund or the Investment Adviser makes available any promotional materials related to the Securities or the transactions contemplated hereby intended for use only by registered broker-dealers and registered representatives thereof by means of an Internet web site or similar electronic means, the Investment Adviser will install and maintain or will cause to be installed and maintained, pre-qualification and password-protection or similar procedures which are reasonably designed to effectively prohibit access to such promotional materials by persons other than registered broker-dealers and registered representatives thereof.

  • Regulatory Materials (a) On a Program-by-Program basis, commencing on the Effective Date until the Regulatory Transfer Date, Prothena shall have the right, in consultation with Celgene, to prepare, file and maintain all Regulatory Materials (including any Regulatory Approvals) necessary for the Development and Manufacture of any Collaboration Candidates and Collaboration Products for such Program (collectively, the “Program Regulatory Materials”), and to interact with Regulatory Authorities in connection with the Development and Manufacture of any Collaboration Candidates and Collaboration Products for such Program. Prothena will provide Celgene with a reasonable opportunity to comment substantively on all material Regulatory Materials prior to filing or taking material action, and will reasonably and in good faith consider any comments and actions recommended by Celgene, including with respect to filing strategy. In addition, Prothena will allow Celgene or its representative to attend any and all meetings with Regulatory Authorities to the extent such attendance is not prohibited or limited by such Regulatory Authority. (b) If Celgene exercises its Phase 1 Portion Participation Right for a given Program, then immediately after such exercise, Prothena shall initiate the transfer of all Program Regulatory Materials, including for clarity any IND for the relevant Collaboration Candidates and/or Collaboration Products that are the subject of such Program to Celgene. The date on which such Program Regulatory Materials are transferred to Celgene shall be the “Regulatory Transfer Date” for such Program. Thereafter, Celgene shall have the right, in consultation with Prothena, to prepare, file, and maintain such Program Regulatory Materials, and to interact with Regulatory Authorities in connection with the Development and, as applicable, Manufacture of such Collaboration Candidates and Collaboration Products for such Program in accordance with the terms and conditions of Section 2.5. Additionally, with respect to any Phase 1 Clinical Trial conducted by Celgene pursuant to Section 2.5, Celgene will provide Prothena with a reasonable opportunity to comment substantively on all material Program Regulatory Materials prior to filing or taking material action, and will reasonably and in good faith consider any comments and actions recommended by Prothena, including with respect to filing strategy. In addition, with respect to any Phase 1 Clinical Trial conducted by Celgene pursuant to Section 2.5, Celgene will allow Prothena or its representative to attend any and all meetings with Regulatory Authorities to the extent such attendance is not prohibited or limited by such Regulatory Authority. For clarity, if the Regulatory Transfer Date does not occur prior to the expiration of the Option Term for such Program, Section 2.6.1(a) (and not this Section 2.6.1(b)) shall apply.

  • Product Information EPIZYME recognizes that by reason of, inter alia, EISAI’s status as an exclusive licensee in the EISAI Territory under this Agreement, EISAI has an interest in EPIZYME’s retention in confidence of certain information of EPIZYME. Accordingly, until the end of all Royalty Term(s) in the EISAI Territory, EPIZYME shall keep confidential, and not publish or otherwise disclose, and not use for any purpose other than to fulfill EPIZYME’s obligations, or exercise EPIZYME’s rights, hereunder any EPIZYME Know-How Controlled by EPIZYME or EPIZYME Collaboration Know-How, in each case that are primarily applicable to EZH2 or EZH2 Compounds (the “Product Information”), except to the extent (a) the Product Information is in the public domain through no fault of EPIZYME, (b) such disclosure or use is expressly permitted under Section 9.3, or (c) such disclosure or use is otherwise expressly permitted by the terms and conditions of this Agreement. For purposes of Section 9.3, each Party shall be deemed to be both the Disclosing Party and the Receiving Party with respect to Product Information. For clarification, the disclosure by EPIZYME to EISAI of Product Information shall not cause such Product Information to cease to be subject to the provisions of this Section 9.2 with respect to the use and disclosure of such Confidential Information by EPIZYME. In the event this Agreement is terminated pursuant to Article 12, this Section 9.2 shall have no continuing force or effect, but the Product Information, to the extent disclosed by EPIZYME to EISAI hereunder, shall continue to be Confidential Information of EPIZYME, subject to the terms of Sections 9.1 and 9.3 for purposes of the surviving provisions of this Agreement. Each Party shall be responsible for compliance by its Affiliates, and its and its Affiliates’ respective officers, directors, employees and agents, with the provisions of Section 9.1 and this Section 9.2.